BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gebremeskel S, Schanin J, Coyle KM, Butuci M, Luu T, Brock EC, Xu A, Wong A, Leung J, Korver W, Morin RD, Schleimer RP, Bochner BS, Youngblood BA. Mast Cell and Eosinophil Activation Are Associated With COVID-19 and TLR-Mediated Viral Inflammation: Implications for an Anti-Siglec-8 Antibody. Front Immunol 2021;12:650331. [PMID: 33777047 DOI: 10.3389/fimmu.2021.650331] [Cited by in Crossref: 3] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Içten S, Ergen P, Aydin Ö, Inal FY, Koruk S, Pamukcu MN, Eken E, Uzunlulu M, Koçoğlu H, Arslan F, Vahaboglu H. The Outcome of High-Dose Corticosteroid Treatment Among Coronavirus Disease 2019 Patients: A Retrospective Cohort Study. Infect Dis Clin Pract 2022;30. [DOI: 10.1097/ipc.0000000000001152] [Reference Citation Analysis]
2 Kell DB, Pretorius E. The potential role of ischaemia-reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications. Biochem J 2022;479:1653-708. [PMID: 36043493 DOI: 10.1042/BCJ20220154] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Raïch-Regué D, Resa-Infante P, Gallemí M, Laguia F, Muñiz-Trabudua X, Muñoz-Basagoiti J, Perez-Zsolt D, Chojnacki J, Benet S, Clotet B, Martinez-Picado J, Izquierdo-Useros N. Role of Siglecs in viral infections: A double-edged sword interaction. Mol Aspects Med 2022;:101113. [PMID: 35981912 DOI: 10.1016/j.mam.2022.101113] [Reference Citation Analysis]
4 Dai Y, Yu H, Yan Q, Li B, Liu A, Liu W, Jiang X, Kim Y, Guo Y, Zhao Z. Drug-Target Network Study Reveals the Core Target-Protein Interactions of Various COVID-19 Treatments. Genes 2022;13:1210. [DOI: 10.3390/genes13071210] [Reference Citation Analysis]
5 Kudryavtsev IV, Golovkin AS, Totolian AA. T helper cell subsets and related target cells in acute COVID-19. Russian Journal of Infection and Immunity 2022;12:409-26. [DOI: 10.15789/2220-7619-thc-1882] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kudryavtsev I, Rubinstein A, Golovkin A, Kalinina O, Vasilyev K, Rudenko L, Isakova-sivak I. Dysregulated Immune Responses in SARS-CoV-2-Infected Patients: A Comprehensive Overview. Viruses 2022;14:1082. [DOI: 10.3390/v14051082] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
7 Jiménez D, Torres Arias M. Immunouniverse of SARS-CoV-2. Immunol Med 2022;:1-39. [PMID: 35502127 DOI: 10.1080/25785826.2022.2066251] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Costanza A, Amerio A, Aguglia A, Serafini G, Amore M, Hasler R, Ambrosetti J, Bondolfi G, Sampogna G, Berardelli I, Fiorillo A, Pompili M, Nguyen KD. Hyper/neuroinflammation in COVID-19 and suicide etiopathogenesis: Hypothesis for a nefarious collision? Neurosci Biobehav Rev 2022;136:104606. [PMID: 35289272 DOI: 10.1016/j.neubiorev.2022.104606] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Wechsler JB, Butuci M, Wong A, Kamboj AP, Youngblood BA. Mast cell activation is associated with post-acute COVID-19 syndrome. Allergy 2022;77:1288-91. [PMID: 34820848 DOI: 10.1111/all.15188] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Korver W, Wong A, Gebremeskel S, Negri GL, Schanin J, Chang K, Leung J, Benet Z, Luu T, Brock EC, Luehrsen K, Xu A, Youngblood BA. The Inhibitory Receptor Siglec-8 Interacts With FcεRI and Globally Inhibits Intracellular Signaling in Primary Mast Cells Upon Activation. Front Immunol 2022;13:833728. [DOI: 10.3389/fimmu.2022.833728] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Karimi N, Morovati S, Chan L, Napoleoni C, Mehrani Y, Bridle BW, Karimi K. Mast Cell Tryptase and Implications for SARS-CoV-2 Pathogenesis. BioMed 2021;1:136-49. [DOI: 10.3390/biomed1020013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Yuge S, Tateishi A, Numata K, Ohmae M. Chemoenzymatic Synthesis of Sialyl Sulfo-Oligosaccharides as Potent Siglec-8 Ligands via Transglycosylation Catalyzed by Keratanase II. Biomacromolecules 2021. [PMID: 34914356 DOI: 10.1021/acs.biomac.1c01289] [Reference Citation Analysis]
13 Khalifa AE, Ghoneim AI. Potential value of pharmacological agents acting on toll-like receptor (TLR) 7 and/or TLR8 in COVID-19. Curr Res Pharmacol Drug Discov 2021;2:100068. [PMID: 34870161 DOI: 10.1016/j.crphar.2021.100068] [Reference Citation Analysis]
14 Dunn JLM, Rothenberg ME. 2021 year in review: Spotlight on eosinophils. J Allergy Clin Immunol 2021:S0091-6749(21)01796-6. [PMID: 34838883 DOI: 10.1016/j.jaci.2021.11.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Kayesh MEH, Kohara M, Tsukiyama-Kohara K. An Overview of Recent Insights into the Response of TLR to SARS-CoV-2 Infection and the Potential of TLR Agonists as SARS-CoV-2 Vaccine Adjuvants. Viruses 2021;13:2302. [PMID: 34835108 DOI: 10.3390/v13112302] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
16 Guillet C, Frischbutter S, Leu N, Schmid-Grendelmeier P. Reply to "The allergic effector unit: From basic science to drug-targetable mast cell-eosinophil interactions in patients". J Allergy Clin Immunol Pract 2021;9:3846-7. [PMID: 34627542 DOI: 10.1016/j.jaip.2021.07.011] [Reference Citation Analysis]
17 Marik PE, Iglesias J, Varon J, Kory P. A scoping review of the pathophysiology of COVID-19. Int J Immunopathol Pharmacol 2021;35:20587384211048026. [PMID: 34569339 DOI: 10.1177/20587384211048026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
18 Tan C, Zheng X, Sun F, He J, Shi H, Chen M, Tu C, Huang Y, Wang Z, Liang Y, Wu J, Liu Y, Liu J, Huang J. Hypersensitivity may be involved in severe COVID-19. Clin Exp Allergy 2021. [PMID: 34570395 DOI: 10.1111/cea.14023] [Reference Citation Analysis]
19 Lam HY, Tergaonkar V, Kumar AP, Ahn KS. Mast cells: Therapeutic targets for COVID-19 and beyond. IUBMB Life 2021;73:1278-92. [PMID: 34467628 DOI: 10.1002/iub.2552] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
20 Hafezi B, Chan L, Knapp JP, Karimi N, Alizadeh K, Mehrani Y, Bridle BW, Karimi K. Cytokine Storm Syndrome in SARS-CoV-2 Infections: A Functional Role of Mast Cells. Cells 2021;10:1761. [PMID: 34359931 DOI: 10.3390/cells10071761] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
21 Islam H, Chamberlain TC, Mui AL, Little JP. Elevated Interleukin-10 Levels in COVID-19: Potentiation of Pro-Inflammatory Responses or Impaired Anti-Inflammatory Action? Front Immunol 2021;12:677008. [PMID: 34234779 DOI: 10.3389/fimmu.2021.677008] [Cited by in F6Publishing: 20] [Reference Citation Analysis]
22 Jiménez M, Cervantes-García D, Córdova-Dávalos LE, Pérez-Rodríguez MJ, Gonzalez-Espinosa C, Salinas E. Responses of Mast Cells to Pathogens: Beneficial and Detrimental Roles. Front Immunol 2021;12:685865. [PMID: 34211473 DOI: 10.3389/fimmu.2021.685865] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
23 Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond) 2021;53:737-54. [PMID: 34024217 DOI: 10.1080/23744235.2021.1924397] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]